The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

被引:237
|
作者
Rosenblat, Joshua D. [1 ,2 ,3 ]
Kakar, Ron [1 ,4 ,5 ]
McIntyre, Roger S. [1 ,2 ,3 ]
机构
[1] Univ Toronto, Univ Hlth Network, Mood Disorder Psychopharmacol Unit, Toronto, ON M5S 1A1, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[3] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[4] Univ Western Ontario, Dept Psychiat, London, ON N6A 3K7, Canada
[5] Univ Western Ontario, Dept Psychiat, Windsor, ON, Canada
来源
关键词
antidepressants; cognitive function; executive function; major depressive disorder; psychomotor speed; working memory; DOUBLE-BLIND; ELDERLY-PATIENTS; FUNCTIONAL OUTCOMES; EFFICACY; PLACEBO; DULOXETINE; PAROXETINE; SERTRALINE; VORTIOXETINE; PERFORMANCE;
D O I
10.1093/ijnp/pyv082
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Cognitive dysfunction is often present in major depressive disorder (MDD). Several clinical trials have noted a pro-cognitive effect of antidepressants in MDD. The objective of the current systematic review and meta-analysis was to assess the pooled efficacy of antidepressants on various domains of cognition in MDD. Methods: Trials published prior to April 15, 2015, were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Data from randomized clinical trials assessing the cognitive effects of antidepressants were pooled to determine standard mean differences (SMD) using a random-effects model. Results: Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified. Antidepressants had a positive effect on psychomotor speed (SMD 0.16; 95% confidence interval [CI] 0.05-0.27; I-2 = 46%) and delayed recall (SMD 0.24; 95% CI 0.15-0.34; I-2 = 0%). The effect on cognitive control and executive function did not reach statistical significance. Of note, after removal of vortioxetine from the analysis, statistical significance was lost for psychomotor speed. Eight head-to-head randomized trials comparing the effects of selective serotonin reuptake inhibitors (SSRIs; n = 371), selective serotonin and norepinephrine reuptake inhibitors (SNRIs; n = 25), tricyclic antidepressants (TCAs; n = 138), and norepinephrine and dopamine reuptake inhibitors (NDRIs; n = 46) were identified. No statistically significant difference in cognitive effects was found when pooling results from head-to-head trials of SSRIs, SNRIs, TCAs, and NDRIs. Significant limitations were the heterogeneity of results, limited number of studies, and small sample sizes. Conclusions: Available evidence suggests that antidepressants have a significant positive effect on psychomotor speed and delayed recall.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Clinical efficacy and economic evaluation of online cognitive behavioral therapy for major depressive disorder: a systematic review and meta-analysis
    Ahern, Elayne
    Kinsella, Stephen
    Semkovska, Maria
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (01) : 25 - 41
  • [42] Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis
    Gill, Hartej
    Chen-Li, David C. J.
    Haikazian, Sipan
    Seyedin, Sam
    McIntyre, Roger S.
    Mansur, Rodrigo B.
    DiVincenzo, Joshua D.
    Phan, Lee
    Rosenblat, Joshua D.
    CNS SPECTRUMS, 2024, 29 (04) : 233 - 242
  • [43] Effectiveness of yoga for major depressive disorder: A systematic review and meta-analysis
    Wu, Yufei
    Yan, Danni
    Yang, Jianli
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [44] Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis
    Kennis, Mitzy
    Gerritsen, Lotte
    van Dalen, Marije
    Williams, Alishia
    Cuijpers, Pim
    Bockting, Claudi
    MOLECULAR PSYCHIATRY, 2020, 25 (02) : 321 - 338
  • [45] Epidemiology of Major Depressive Disorder in Iran: A Systematic Review and Meta-Analysis
    Sadeghirad, Behnam
    Haghdoost, Ali-Akbar
    Amin-Esmaeili, Masoumeh
    Ananloo, Esmaeil Shahsavand
    Ghaeli, Padideh
    Rahimi-Movaghar, Afarin
    Talebian, Elham
    Pourkhandani, Ali
    Noorbala, Ahmad Ali
    Barooti, Esmat
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2010, 1 (02) : 81 - 91
  • [46] Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis
    Etchecopar-Etchart, Damien
    Korchia, Theo
    Loundou, Anderson
    Llorca, Pierre-Michel
    Auquier, Pascal
    Lancon, Christophe
    Boyer, Laurent
    Fond, Guillaume
    SCHIZOPHRENIA BULLETIN, 2021, 47 (02) : 298 - 308
  • [47] Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis
    Ahmad, Abdullah
    Awan, Abdul Rafeh
    Nadeem, Natasha
    Javed, Aamir Shahid
    Farooqi, Mobeen
    Daniyal, Muhammed
    Mumtaz, Hassan
    FRONTIERS IN NEUROSCIENCE, 2024, 18
  • [48] Gut microbiota and major depressive disorder: A systematic review and meta-analysis
    Sanada, Kenji
    Nakajima, Shinichiro
    Kurokawa, Shunya
    Barcelo-Soler, Alberto
    Ikuse, Daisuke
    Hirata, Akihito
    Yoshizawa, Akira
    Tomizawa, Yoshihiro
    Salas-Valero, Montserrat
    Noda, Yoshihiro
    Mimura, Masaru
    Iwanami, Akira
    Kishimoto, Taishiro
    JOURNAL OF AFFECTIVE DISORDERS, 2020, 266 : 1 - 13
  • [49] Cortical thickness in major depressive disorder: A systematic review and meta-analysis
    Suh, Jee Su
    Schneider, Maiko Abel
    Minuzzi, Luciano
    MacQueen, Glenda M.
    Strother, Stephen C.
    Kennedy, Sidney H.
    Frey, Benicio N.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 88 : 287 - 302
  • [50] Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis
    Nishi, Akira
    Sawada, Kyosuke
    Uchida, Hiroyuki
    Mimura, Masaru
    Takeuchi, Hiroyoshi
    PHARMACOPSYCHIATRY, 2023, 56 (01) : 5 - 17